Q2 2026 Denali Therapeutics Inc Earnings Call Transcript
Key Points
- Denali Therapeutics Inc (DNLI) reported strong early launch momentum for AVLAYAH, with $3.6 million in net product revenue in its first full commercial quarter and Q3 guidance of $10-12 million, indicating faster-than-expected adoption.
- The company has secured commercial payer coverage for more than 50% of covered lives and 14 state Medicaid programs, which is favorable compared to analogous rare disease launches.
- Denali Therapeutics Inc (DNLI) advanced two Alzheimer's disease programs (DNL628 and DNL921) into clinical development, with initial data expected in 2027, expanding its pipeline into large-market opportunities.
- The company strengthened its financial position with over $1.1 billion in pro forma cash after selling its Priority Review Voucher for $195 million, providing flexibility for commercial and pipeline investments.
- Denali Therapeutics Inc (DNLI) received Orphan Drug Designation for DNL593 (FTD-GRN) and regained full ownership, allowing for strategic flexibility and a potential biomarker-driven accelerated approval path.
- Denali Therapeutics Inc (DNLI) faces uncertainty regarding the sustainability of the AVLAYAH launch trajectory, as the initial demand may represent a bolus effect from highly engaged families that could attenuate over time.
- The company delayed DNL593 data readout to the first half of 2027, citing the need for longer observation to characterize treatment effects on biomarkers like NfL, which may disappoint investors expecting near-term results.
- Denali Therapeutics Inc (DNLI) has not provided detailed patient numbers or start form metrics, limiting visibility into the launch's underlying drivers and making it difficult to assess the durability of revenue growth.
- The company faces competitive threats in the Hunter syndrome market, including potential resubmissions and global Phase 3 readouts from competitors like JCR's JR-141, which could impact AVLAYAH's market share.
- Denali Therapeutics Inc (DNLI) acknowledged that the Alzheimer's disease field is complex, with challenges in comparing efficacy across different delivery methods (intrathecal vs. intravenous) and managing co-pathologies, which could complicate clinical development and regulatory approval.
Good day, and thank you for standing by. Welcome to the second quarter 2026 financial results and business highlights conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised.
To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Laura Hansen. Please go ahead.
Good afternoon, everyone, and thank you for joining us today to discuss Denali Therapeutics' second quarter 2026 financial results and business highlights. Earlier today, we issued our earnings press release and filed our quarterly report. The press release, financial tables, and today's presentation are available in the Investor Relations
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
